Valuation: ALLOVIRPAR

Market Cap 49.21M 43.01M 40.42M 36.89M 69.23M 4.7B 69.24M 485M 187M 2.4B 185M 181M 7.75B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -60.37M -56.74M -51.78M -97.17M -6.6B -97.19M -681M -263M -3.37B -259M -254M -10.87B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-0.15%
Current month-66.97%
Current year-66.97%
3 years 3.16
Extreme 3.16
58.3
5 years 3.16
Extreme 3.16
607.43
10 years 3.16
Extreme 3.16
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -166M -156M -143M -268M -18.2B -268M -1.88B -724M -9.3B -715M -699M -29.97B -58.77M -51.36M -48.27M -44.05M -82.67M -5.62B -82.69M -579M -224M -2.87B -221M -216M -9.25B
Net Debt -157M -137M -129M -117M -220M -14.96B -220M -1.54B -595M -7.64B -588M -575M -24.63B -118M -103M -97.16M -88.66M -166M -11.31B -166M -1.17B -450M -5.77B -444M -434M -18.62B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change
22/09/26 $3.240 -0.15%
21/09/26 $3.245 +1.41%
18/09/26 $3.200 +1.27%
17/09/26 $3.160 -0.63%
16/09/26 $3.180 -0.63%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!